MedTrace Logo

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-09-13

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection

Conditions

  • Kidney Transplant
  • Hepatitis C
  • HCV

Interventions

DRUG

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]

fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C

DRUG

Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]

Three tablets once a day for 12 weeks for treatment of hepatitis C

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Reem Daloul, MD · Ohio State University School of Biomedical Science: The Ohio State University College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2021-04-28
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801707 on ClinicalTrials.gov